ACT-451840

• Description:

  ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial[1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Parasite

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/act-451840.html

• Concentration:

  10mM

• Purity:

  96.45

• Solubility:

  DMSO : 41.67 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C (N (CC1=CC=C (N2CCN (C (C) =O) CC2) C=C1) [C@@H] (CC3=CC=CC=C3) C (N4CCN (CC5=CC=C (C#N) C=C5) CC4) =O) /C=C/C6=CC=C (C (C) (C) C) C=C6

• Molecular Formula:

  C47H54N6O3

• Molecular Weight:

  750.97

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Bruderer S, et al. First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. Antimicrob Agents Chemother. 2015;59 (2) :935-942.|[2]Boss C, et al. Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action. ChemMedChem. 2016;11 (18) :1995-2014.|[3]Le Bihan A, et al. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. PLoS Med. 2016;13 (10) :e1002138. Published 2016 Oct 4.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  Plasmodium

• CAS Number:

  1984890-99-4